LivingGLP1
Study S001745

Evaluation of the Relationship Between GLP-1 Receptor Agonist Use and Sarcopenia in Non-Diabetic Obese Individuals: A Prospective Descriptive Study

ClinicalTrials.gov record

Registration

Registration
NCT07858864
Acronym
GLP1-SARCO
Study type
OBSERVATIONAL
Status
RECRUITING
Enrollment
42
Start
2026-05-30
Primary completion
2026-11-30
Lead sponsor
Istanbul Saglik Bilimleri University
Conditions
Obesity; Sarcopenia
Interventions
DRUG:GLP-1 receptor agonist (e.g., semaglutide, tirzepatide) - prescribed by the treating physician as standard care; the study does not assign or alter treatment.
Results posted
FALSE
Individual participant data sharing
UNDECIDED

Registered primary outcomes

  • Change in SARC-F (Strength, Assistance in walking, Rise from a chair, Climb stairs, and Falls) total score [Baseline (GLP-1 RA initiation) and 3 months]

Linked records (3)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.
RecordTitleYearDesignIdentifiersLink basis
R0006082Effect of the glucagon-like peptide-1 receptor agonist liraglutide, compared to caloric restriction, on appetite, dietary intake, body fat distribution and cardiometabolic biomarkers: A randomized trial in adults with obesity and prediabetes.
Silver HJ, Diabetes, obesity & metabolism
2023Randomized trialPMID 37188932DOIregistry reference BACKGROUND:37188932
R0008912Safety and tolerability of semaglutide across the SUSTAIN and PIONEER phase IIIa clinical trial programmes.
Aroda VR, Diabetes, obesity & metabolism
2023Randomized trialPMID 36700417DOIregistry reference BACKGROUND:36700417
R0008567A Review of the Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors on Lean Body Mass in Humans.
Sargeant JA, Endocrinology and metabolism (Seoul, Korea)
2019Narrative reviewPMID 31565876DOIregistry reference BACKGROUND:31565876